152 related articles for article (PubMed ID: 20853029)
21. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
Clemons KV; Espiritu M; Parmar R; Stevens DA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
[TBL] [Abstract][Full Text] [Related]
22. Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis.
Chamilos G; Kontoyiannis DP
J Infect; 2005 Nov; 51(4):e225-8. PubMed ID: 16291275
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of triazoles in a murine disseminated infection by Candida krusei.
Mariné M; Pastor FJ; Serena C; Guarro J
Antimicrob Agents Chemother; 2009 Aug; 53(8):3585-8. PubMed ID: 19470509
[TBL] [Abstract][Full Text] [Related]
24. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice.
Capilla J; Serena C; Pastor FJ; Ortoneda M; Guarro J
Antimicrob Agents Chemother; 2003 Dec; 47(12):3976-8. PubMed ID: 14638514
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani.
Guarro J; Pujol I; Mayayo E
Antimicrob Agents Chemother; 1999 May; 43(5):1256-7. PubMed ID: 10223945
[TBL] [Abstract][Full Text] [Related]
27. Improving the mouse model for studying the efficacy of voriconazole.
Graybill JR; Najvar LK; Gonzalez GM; Hernandez S; Bocanegra R
J Antimicrob Chemother; 2003 Jun; 51(6):1373-6. PubMed ID: 12746374
[TBL] [Abstract][Full Text] [Related]
28. Voriconazole and fungal keratitis: a report of two treatment failures.
Giaconi JA; Marangon FB; Miller D; Alfonso EC
J Ocul Pharmacol Ther; 2006 Dec; 22(6):437-9. PubMed ID: 17238810
[TBL] [Abstract][Full Text] [Related]
29. [The role of voriconazole in the treatment of emerging mycoses].
Pastor FJ; Guarro J
Rev Iberoam Micol; 2007 Sep; 24(3):228-32. PubMed ID: 17874861
[TBL] [Abstract][Full Text] [Related]
30. In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method.
Taj-Aldeen SJ; Salah H; Al-Hatmi AM; Hamed M; Theelen B; van Diepeningen AD; Boekhout T; Lass-Flörl C
Diagn Microbiol Infect Dis; 2016 Aug; 85(4):438-43. PubMed ID: 27312690
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole.
Klont RR; Eggink CA; Rijs AJ; Wesseling P; Verweij PE
Clin Infect Dis; 2005 Jun; 40(12):e110-2. PubMed ID: 15909252
[TBL] [Abstract][Full Text] [Related]
32. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia.
Rieger C; Geiger S; Herold T; Nickenig C; Ostermann H
Eur J Clin Microbiol Infect Dis; 2007 Nov; 26(11):843-5. PubMed ID: 17690928
[TBL] [Abstract][Full Text] [Related]
33. Acremonium sclerotigenum-Acremonium egyptiacum: a multi-resistant fungal pathogen complicating the course of aplastic anaemia.
Guitard J; Degulys A; Buot G; Aline-Fardin A; Dannaoui E; Rio B; Marie JP; Lapusan S; Hennequin C
Clin Microbiol Infect; 2014 Jan; 20(1):O30-2. PubMed ID: 23991697
[TBL] [Abstract][Full Text] [Related]
34. The fusarium keratitis outbreak: not done yet?
Jeng BH; Hall GS; Schoenfield L; Meisler DM
Arch Ophthalmol; 2007 Jul; 125(7):981-3. PubMed ID: 17620587
[No Abstract] [Full Text] [Related]
35. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
Silva EG; Paula CR; de Assis Baroni F; Gambale W
Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B.
Stanzani M; Vianelli N; Bandini G; Paolini S; Arpinati M; Bonifazi F; Giannini B; Agostinelli C; Baccarani M; Ricci P
J Infect; 2006 Dec; 53(6):e243-6. PubMed ID: 16584783
[TBL] [Abstract][Full Text] [Related]
37. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
38. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii.
Li H; Lu Q; Wan Z; Zhang J
Int J Antimicrob Agents; 2010 Jun; 35(6):550-2. PubMed ID: 20202797
[TBL] [Abstract][Full Text] [Related]
39. Voriconazole.
Med Lett Drugs Ther; 2002 Jul; 44(1135):63-5. PubMed ID: 12138377
[No Abstract] [Full Text] [Related]
40. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
